COVID-19: Ivermectin; Molecular Mechanisms, Limitations, Suggestions

COVID-19: Ivermectin; Molecular Mechanisms, Limitations, Suggestions

To date, no effective treatment has been found against coronaviruses (CoVs), which have re-emerged with severe acute respiratory syndrome CoV-2 (SARS-CoV-2) and have a high potential for disease in humans as well as domestic and wild animal species. The investigation of treatment options to combat t...

Full description

Bibliographic Details
Main Authors:	Mustafa KESMEN, Ceren ANLAŞ, Tülay BAKIREL, Eray Metin GÜLER
Format:	Article
Language:	English
Published:	Galenos Publishing House 2020-12-01
Series:	Bezmiâlem Science
Subjects:	antiviral efficacy covid-19 drug repurposing ivermectin sars-cov-2
Online Access:	http://bezmialemscience.org/archives/archive-detail/article-preview/covd-19-vermectin-molecular-mechanisms-limitations/42779

Similar Items

Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens
by: Georgi Momekov, et al.
Published: (2020-01-01)

Role of ivermectin in COVID-19: Wishful thinking or scientific optimism
by: Prafull Mohan, et al.
Published: (2020-01-01)

Use of ivermectin in the treatment of Covid-19: A pilot trial
by: Henrique Pott-Junior, et al.
Published: (2021-01-01)

An Overview of COVID-19 Medicines in Current Guidelines
by: Mustafa GÖKÇE, et al.
Published: (2020-12-01)

Antiviral Activity of Ivermectin Against SARS-CoV-2: An Old-Fashioned Dog with a New Trick—A Literature Review
by: Mudatsir Mudatsir, et al.
Published: (2020-08-01)

Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?
by: David A. Jans, et al.
Published: (2020-09-01)

Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients
by: Nurullah Okumuş, et al.
Published: (2021-05-01)

A five-day course of ivermectin may reduce the duration of COVID-19 illness
by: Sabeena Ahmed, et al.
Published: (2021-09-01)

Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities
by: Zena Wehbe, et al.
Published: (2021-03-01)

A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
by: Sabeena Ahmed, et al.
Published: (2021-02-01)

Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-Analysis
by: Mario Cruciani, et al.
Published: (2021-09-01)

Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review
by: Bruno Silva Andrade, et al.
Published: (2020-12-01)

Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial
by: Laurens Liesenborghs, M.D., et al.
Published: (2021-04-01)

Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial
by: Morteza Shakhsi Niaee, et al.
Published: (2021-01-01)

The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial
by: Carlos Chaccour, et al.
Published: (2021-02-01)

Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19
by: Khan Sharun, et al.
Published: (2020-05-01)

No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison
by: Roberta Gagliardini, et al.
Published: (2021-04-01)

Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19
by: A.D. Santin, et al.
Published: (2021-09-01)

CDC Warns of Increased Ivermectin Overdoses
by: Richard A. Robbins, MD
Published: (2021-08-01)

Attenuation of clinical and immunological outcomes during SARS‐CoV‐2 infection by ivermectin
by: Guilherme Dias deMelo, et al.
Published: (2021-08-01)

Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico
by: René Lima-Morales, et al.
Published: (2021-04-01)

Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19
by: Rudra P. Saha, et al.
Published: (2020-08-01)

Efficacy of Novel Formulations of Ivermectin and Albendazole in Parasitic Infections of Sheep in the Altai Mountains of Russia
by: Victor Alexeevich Marchenko, et al.
Published: (2021-05-01)

Valinomycin as a potential antiviral agent against coronaviruses: A review
by: Dong Zhang, et al.
Published: (2020-10-01)

Efficacy of High-Dose Albendazole with Ivermectin for Treating Imported Loiasis, Italy
by: Federico Gobbi, et al.
Published: (2019-08-01)

A Rapid Strategy for Repurposing Drugs for COVID-19
by: Maryam Khoubnasabjafari, et al.
Published: (2020-11-01)

Anthelmintic Efficacy and Pharmacokinetics of Ivermectin Paste after Oral Administration in Mules Infected by Cyathostomins
by: Marilena Bazzano, et al.
Published: (2020-05-01)

Antiviral Effects of Ivermectin in COVID-19- Clinically Plausible?
by: Dr. Ajay Kumar Shukla, et al.
Published: (2021-08-01)

Аntiparasitic complex of Ivermectin for treatment of herd horses at gastrointestinal Nematodosis
by: М. В. Musaev, et al.
Published: (2020-06-01)

FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2
by: Ahmed Mostafa, et al.
Published: (2020-12-01)

Identification of potential antivirals against SARS-CoV-2 using virtual screening method
by: Mohammad Rejaur Rahman, et al.
Published: (2021-01-01)

An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics
by: Dongyuan Wang, et al.
Published: (2020-10-01)

In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds
by: Aminpour, M., et al.
Published: (2022)

Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection
by: Brian C. Procter, et al.
Published: (2020-12-01)

Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon
by: Ali A. Samaha, et al.
Published: (2021-05-01)

Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2
by: Ahmad F. Eweas, et al.
Published: (2021-01-01)

Treatment Options for COVID-19: A Review
by: Mukarram Jamat Ali, et al.
Published: (2020-07-01)

Repurposing of antibiotics for clinical management of COVID-19: a narrative review
by: Abdourahamane Yacouba, et al.
Published: (2021-05-01)

Esophageal deformation of Gnathostoma spinigerum in ivermectin-treated rats, and anthelminthic efficacy
by: Anantaphruti M., et al.
Published: (2010-06-01)

Recent advances in management of COVID-19: A review
by: Soraya Mouffak, et al.
Published: (2021-11-01)